Commercial opportunities for an automated extracellular vesicle biofoundry

自动化细胞外囊泡生物铸造厂的商业机会

• 批准号: BB/T017147/1
• 负责人: Paul Freemont
• 金额: $ 19.12万
• 依托单位: Imperial College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=BB%2FT017147%2F1
• 关键词: Commercial; opportunities; automated; extracellular; vesicle

Our cells produce and secret tiny extracellular vesicles, called exosomes which are essentially molecular messages that cells send to each other. Exosomes are composed of many different molecular components, including proteins, that are encased in a lipd (fat) bilayer. Exosomes help to keep us healthy and have many different roles in the body. Ongoing research has also shown that exosomes could potentially be used as therapies to treat diseases including cancers. Unfortunately, there are limitations with current exosome manufacturing methods which are making it difficult to produce enough exosomes for larger studies. Essentially, it is difficult to generate enough exosomes to begin the larger scale experiments and clinical trials needed to safely test and develop exosomes. For several years we have been developing new methods to manufacture therapeutic exosomes. However, we are still at a relatively early stage of development. With additional support we reach a stage of development where we can more easily collaborate with pharmaceutical companies to accelerate this promising new therapeutic class.

我们的细胞产生并分泌微小的细胞外囊泡，称为外泌体，它本质上是细胞相互发送的分子信息。外泌体由许多不同的分子成分组成，包括蛋白质，它们被包裹在lipd（脂肪）双层中。外泌体有助于保持我们的健康，并在体内发挥许多不同的作用。正在进行的研究还表明，外泌体可能被用作治疗包括癌症在内的疾病的疗法。不幸的是，目前的外泌体制造方法存在局限性，这使得难以为更大规模的研究生产足够的外泌体。从本质上讲，很难产生足够的外泌体来开始安全测试和开发外泌体所需的更大规模的实验和临床试验。几年来，我们一直在开发制造治疗性外泌体的新方法。然而，我们仍然处于相对早期的发展阶段。在额外的支持下，我们达到了一个发展阶段，在这个阶段，我们可以更容易地与制药公司合作，加速这一有前途的新治疗类别。

项目成果

AL-PHA beads: bioplastic-based protease biosensors for global health applications

AL-PHA 珠：用于全球健康应用的基于生物塑料的蛋白酶生物传感器

• DOI: 10.1101/2020.06.18.159921
• 发表时间: 2020
• 作者: Kelwick R